Skip to main content
SpringerLink
Log in

Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality

  • Suicide (R Liu, Section Editor)
  • Published:
Current Behavioral Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Given recent increases in rates of suicide and lack of rapid treatments for suicidality, ketamine has been identified as a potential fast-acting anti-suicidal treatment. Our review seeks to describe the effects of ketamine on suicidality, given the growing literature on the use of ketamine in reducing suicidality. We examine open-label studies and randomized controlled trials evaluating the treatment of suicidality with ketamine. Furthermore, our manuscript identifies potential mechanisms of ketamine’s effects on suicidality.

Recent Findings

Based on existing RCTs, ketamine appears to have rapid anti-suicidal effects, with most literature studying such effects in timeframes less than 1 week. Although still in the early stages of research, mechanisms of ketamine include modulation of molecular, inflammatory, neural, cognitive, and behavioral processes.

Summary

Thus, ketamine appears to be a promising treatment for suicidality but requires larger scale and more robust RCTs to confirm the potential use of this agent in clinical settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Web-based Injury Statistics Query and Reporting System (WISQARS) [Online] 2019 [cited 2019 April 24]; Available from: www.cdc.gov/ncipc/wisqars.

  2. Organization, W.H. Suicide 2018 August 24, 2018 [cited 2019 April 24]; Available from: https://www.who.int/news-room/fact-sheets/detail/suicide.

  3. Increase in suicide in the United States 1999–2014. 2016: Hyattsville, MD.

  4. Meerwijk EL, et al. Direct versus indirect psychosocial and behavioural interventions to prevent suicide and suicide attempts: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(6):544–54.

    PubMed  Google Scholar 

  5. Al Jurdi RK, Swann A, Mathew SJ. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015;17(10):81.

    PubMed  Google Scholar 

  6. McGirr A, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704.

    CAS  PubMed  Google Scholar 

  7. Iadarola ND, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6(3):97–114.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Price RB, Mathew SJ. Does ketamine have anti-suicidal properties? Current status and future directions. CNS drugs. 2015;29(3):181–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Andrade C. Ketamine for Depression, 6: Effects on Suicidal Ideation and Possible Use as Crisis Intervention in Patients at Suicide Risk. The Journal of clinical psychiatry. 2018. 79(2).

    PubMed  Google Scholar 

  10. Ionescu DF, et al. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. J Clin Psychiatry. 2016;77(6):e719–25.

    PubMed  Google Scholar 

  11. Zheng W, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res. 2018;106:61–8.

    PubMed  Google Scholar 

  12. Zarate CA Jr, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Nugent AC, et al. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Molecular psychiatry. 2018: p. 1.

    PubMed  PubMed Central  Google Scholar 

  14. Chen M-H, et al. Antisuicidal Effect, BDNF Val66Met Polymorphism, and Low-Dose Ketamine Infusion: Reanalysis of Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression (AKSTP-TRS). Journal of Affective Disorders. 2019.

  15. Ionescu DF, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516–24.

    CAS  PubMed  Google Scholar 

  16. Price RB, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4):335–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Murrough JW, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571–80.

    CAS  PubMed  Google Scholar 

  18. Grunebaum MF, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar disorders. 2017;19(3):176–83.

    CAS  PubMed  Google Scholar 

  19. Grunebaum MF, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2018;175(4):327–35.

    PubMed  Google Scholar 

  20. Hu YD, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46(3):623–35.

    PubMed  Google Scholar 

  21. Canuso CM, et al. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry. 2018;175(7):620–30.

    PubMed  Google Scholar 

  22. Zarate CA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of general psychiatry. 2006;63(8):856–64.

    CAS  PubMed  Google Scholar 

  23. Singh JB, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. American Journal of Psychiatry. 2016;173(8):816–26.

    PubMed  Google Scholar 

  24. Domany Y, Lord J, and McCullumsmith CB. Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial. An Emergency Department, Trans-Diagnostic Approach: Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial (April 5, 2019), 2019.

  25. Wilkinson ST, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American journal of psychiatry. 2017;175(2):150–8.

    PubMed  Google Scholar 

  26. Burger J, et al. A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting. Mil Med. 2016;181(10):1195–9.

    PubMed  Google Scholar 

  27. Fan W, et al. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. Oncotarget. 2017;8(2):2356.

    PubMed  Google Scholar 

  28. Kudoh A, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesthesia & Analgesia. 2002;95(1):114–8.

    CAS  Google Scholar 

  29. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.

    CAS  PubMed  Google Scholar 

  30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7(0):151–69.

    CAS  PubMed  Google Scholar 

  32. Rush AJ, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–83.

    PubMed  Google Scholar 

  33. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the Scale for Suicide Ideation. J Consult Clin Psychol. 1979;47(2):343–52.

    CAS  PubMed  Google Scholar 

  34. Beck AT, Steer RA, Ranieri WF. Scale for Suicide Ideation: psychometric properties of a self-report version. J Clin Psychol. 1988;44(4):499–505.

    CAS  PubMed  Google Scholar 

  35. Posner K, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–77.

    PubMed  PubMed Central  Google Scholar 

  36. Price RB, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5):522–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. DiazGranados N, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Thakurta RG, et al. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med. 2012;34(2):170–5.

    PubMed  PubMed Central  Google Scholar 

  39. Ballard ED, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–6.

    PubMed  Google Scholar 

  40. Wilkinson ST, et al. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019: p. 1.

  41. Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide. Available from: https://ClinicalTrials.gov/show/NCT03666390.

  42. Intranasal Ketamine for Suicidal Ideation in Veterans. Available from: https://ClinicalTrials.gov/show/NCT03788694.

  43. Oral Ketamine for Suicidal Ideation. Available from: https://ClinicalTrials.gov/show/NCT02037503.

  44. Bartoli F, et al. Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neurosci Biobehav Rev. 2017;77:232–6.

    CAS  PubMed  Google Scholar 

  45. Zhou Y, et al. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain Behav Immun. 2018;74:205–12.

    CAS  PubMed  Google Scholar 

  46. Lopez-Diaz A, et al. Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain. Ther Adv Psychopharmacol. 2017;7(4):137–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Li Z, et al. Attributable risk of psychiatric and socio-economic factors for suicide from individual-level, population-based studies: a systematic review. Soc Sci Med. 2011;72(4):608–16.

    PubMed  Google Scholar 

  48. Conwell Y, et al. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry. 1996;153(8):1001–8.

    CAS  PubMed  Google Scholar 

  49. Franklin JC, et al. Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research. Psychol Bull. 2017;143(2):187–232.

    PubMed  Google Scholar 

  50. Ballard ED, et al. Characterizing the course of suicidal ideation response to ketamine. J Affect Disord. 2018;241:86–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Mallick F, McCullumsmith CB. Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. Curr Psychiatry Rep. 2016;18(6):61.

    PubMed  Google Scholar 

  52. Fava M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular psychiatry. 2018: p. 1.

  53. Xu Y, et al., Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology. 2016; 19(4).

    PubMed Central  Google Scholar 

  54. Kashani P, et al. The effect of intravenous ketamine in suicidal ideation of emergency department patients. Emergency. 2014;2(1):36.

    PubMed  PubMed Central  Google Scholar 

  55. Vidal S, et al. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study. J Clin Psychopharmacol. 2018;38(6):590–7.

    CAS  PubMed  Google Scholar 

  56. Wilkinson ST, et al. Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. Biol Psychiatry. 2019;85(6):454–65.

    PubMed  Google Scholar 

  57. Ballard ED and Price RB. Ketamine for treatment-resistant depression. Mathew CAZSJ, Mathew SJ, and Zarate CA Jr, Editors. 2016, Springer.

  58. Dadiomov D, Lee K. The effects of ketamine on suicidality across various formulations and study settings. Ment Health Clin. 2019;9(1):48–60.

    PubMed  PubMed Central  Google Scholar 

  59. Peltoniemi MA, et al. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Clin Pharmacokinet. 2016;55(9):1059–77.

    CAS  PubMed  Google Scholar 

  60. Li L, Vlisides PE. Ketamine: 50 Years of Modulating the Mind. Front Hum Neurosci. 2016;10:612.

    PubMed  PubMed Central  Google Scholar 

  61. Molero P, et al. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review. CNS Drugs. 2018;32(5):411–20.

    CAS  PubMed  Google Scholar 

  62. Zanos P, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018;70(3):621–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Food_and_Drug_Administration. Highlights Of Prescribing Information: Spravato (esketamine) nasal spray. 2019 [cited 2019; Available from: https://www.accessdata.fda.gov.

  64. Rosenblat JD, et al. Oral Ketamine for Depression: A Systematic Review. J Clin Psychiatry. 2019; 80(3).

  65. Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Res. 2018; 7.

  66. Hodes GE, et al. Neuroimmune mechanisms of depression. Nat Neurosci. 2015;18(10):1386–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. De Berardis D, et al. Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. International journal of molecular sciences. 2018;19(10):2888.

    PubMed Central  Google Scholar 

  68. Cui W et al. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine’s Antidepressant Effect. Molecular neurobiology. 2018; p. 1-17

  69. Chang Y, et al. Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm. 2009;2009:705379.

    PubMed  PubMed Central  Google Scholar 

  70. Yang C, et al. Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus. Experimental and therapeutic medicine. 2013;5(4):1093–6.

    PubMed  PubMed Central  Google Scholar 

  71. Kiraly DD, et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017;7(3):e1065.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Chen MH, et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study. Psychiatry Res. 2018;269:207–11.

    CAS  PubMed  Google Scholar 

  73. Park M, et al. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. Journal of psychiatric research. 2017;84:113–8.

    PubMed  Google Scholar 

  74. Black C, Miller BJ. Meta-Analysis of Cytokines and Chemokines in Suicidality: Distinguishing Suicidal Versus Nonsuicidal Patients. Biol Psychiatry. 2015;78(1):28–37.

    CAS  PubMed  Google Scholar 

  75. Ducasse D, et al. A meta-analysis of cytokines in suicidal behavior. Brain Behav Immun. 2015;46:203–11.

    PubMed  Google Scholar 

  76. Yang J-j, et al. Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biological psychiatry. 2015;77(3):e19–20.

    CAS  PubMed  Google Scholar 

  77. Miller AH. Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression. Neuropsychopharmacology. 2013;38(9):1607.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Erhardt S, et al. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology. 2013;38(5):743–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Nock MK, et al. Measuring the suicidal mind: implicit cognition predicts suicidal behavior. Psychol Sci. 2010;21(4):511–7.

    PubMed  PubMed Central  Google Scholar 

  80. Ducasse D, et al. Anhedonia is associated with suicidal ideation independently of depression: A meta-analysis. Depression and anxiety. 2018;35(5):382–92.

    PubMed  Google Scholar 

  81. Thomas RK, et al. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. Journal of psychopharmacology. 2018;32(10):1110–7.

    CAS  PubMed  Google Scholar 

  82. Ballard ED, et al. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. Journal of affective disorders. 2017;218:195–200.

    PubMed  PubMed Central  Google Scholar 

  83. Voort JLV, et al. Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. The Journal of clinical psychiatry. 2017;78(8):1068.

    Google Scholar 

  84. Bani-Fatemi, A., et al., Structural and functional alterations of the suicidal brain: An updated review of neuroimaging studies. Psychiatry Res Neuroimaging, 2018.

  85. Huang X, et al. Brain Abnormalities Associated with Self-Injurious Thoughts and Behaviors: A Meta-Analysis of Neuroimaging Studies. bioRxiv. 2019; p. 526525.

  86. Ionescu DF, et al. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature. Harv Rev Psychiatry. 2018;26(6):320–39.

    PubMed  PubMed Central  Google Scholar 

  87. Myung W, et al. Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder. Transl Psychiatry. 2016;6(6):e835.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Du L, et al. Fronto-limbic disconnection in depressed patients with suicidal ideation: A resting-state functional connectivity study. J Affect Disord. 2017;215:213–7.

    PubMed  Google Scholar 

  89. Ballard ED, et al. Neural correlates of suicidal ideation and its reduction in depression. Int J Neuropsychopharmacol. 2014: 18(1).

    PubMed  Google Scholar 

  90. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci. 2017;42(4):222–9.

    PubMed  PubMed Central  Google Scholar 

  91. Bernstein H-G, et al. Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: survey of the literature and own findings on glutamine synthetase. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders). 2013;12(7):900–13.

    CAS  Google Scholar 

  92. Brent D, Melhem N, Turecki G. Pharmacogenomics of suicidal events. Pharmacogenomics. 2010;11(6):793–807.

    PubMed  PubMed Central  Google Scholar 

  93. Noga JT, et al. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse. 1997;27(3):168–76.

    CAS  PubMed  Google Scholar 

  94. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16(7):472–86.

    CAS  PubMed  Google Scholar 

  95. Zanos P and Gould TD. Mechanisms of ketamine action as an antidepressant. Molecular psychiatry. 2018.

  96. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behavioural brain research. 2011;224(1):107–11.

    CAS  PubMed  Google Scholar 

  97. Williams NR, et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. Am J Psychiatry. 2018;175(12):1205–15.

    PubMed  PubMed Central  Google Scholar 

  98. Schenkel LC, et al. The BDNF Val66Met polymorphism is an independent risk factor for high lethality in suicide attempts of depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34(6):940–4.

    CAS  PubMed  Google Scholar 

  99. Pregelj P, et al. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. Journal of affective disorders. 2011;128(3):287–90.

    CAS  PubMed  Google Scholar 

  100. Flory JD, et al. Gene expression associated with suicide attempts in US veterans. Transl Psychiatry. 2017;7(9):e1226.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. Haile CN, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(2):331–6.

    CAS  PubMed  Google Scholar 

  102. Ballard ED, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015;68:68–73.

    PubMed  PubMed Central  Google Scholar 

  103. Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–4.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Pittsburgh, 3811 O’Hara St, Pittsburgh, PA, 15213, USA

    Manivel Rengasamy & Rebecca B. Price

  2. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Kimberly Hsiung

  3. Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA

    Rebecca B. Price

Authors
  1. Manivel Rengasamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kimberly Hsiung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebecca B. Price
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rebecca B. Price.

Ethics declarations

Conflict of Interest

Manivel Rengasamy, Kimberly Hsiung, and Rebecca Price declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Suicide

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rengasamy, M., Hsiung, K. & Price, R.B. Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality. Curr Behav Neurosci Rep 6, 166–176 (2019). https://doi.org/10.1007/s40473-019-00184-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40473-019-00184-3

Keywords

Search

Navigation